Analyst consensus rating
Immuneering Analyst Rating: none
Direct answer
Immuneering's consensus rating is none.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $17.17.
Forecast evidence checked October 17, 2026.
Get free Immuneering email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.59
- Average price target
- $17.17
- High price target
- $30.00
- Low price target
- $12.00
- Low target gap
- +234.3%
- Target upside
- +378.2%
- High target gap
- +735.7%
- Target range width
- 501.4%
- Consensus rating
- none
- Analysts
- 6
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Immuneering?
Immuneering has a verified none consensus. The same dataset has an average price target of $17.17.
How far are Immuneering's low and high targets from the recorded price?
The low target implies +234.3%, while the high target implies +735.7%.
How many analysts are included in Immuneering's consensus?
The verified consensus includes 6 analysts.
How is Immuneering's target upside or downside calculated?
The average target of $17.17 is divided by the recorded price of $3.59, then one is subtracted to produce +378.2%. This does not guarantee a future return.
When was Immuneering's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.